Iman M, Mirfakhraee S
Department of Pharmaceutics, Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Arch Razi Inst. 2024 Oct 31;79(5):903-914. doi: 10.32592/ARI.2024.79.5.903. eCollection 2024 Oct.
It is well established that infection is a primary cause of gastritis. There is an alarming potential for this infection to progress into gastric cancer if left unaddressed. However, the efficacy of conventional treatments is undermined by the growing challenge of antibiotic resistance and the necessity for complex multidrug and high-dose therapeutic regimens. Furthermore, the presence of factors such as biofilm formation, efflux pumps, and gene mutations significantly elevates the risk of treatment failure. In view of these significant challenges, contemporary drug delivery systems represent a vital adjunct in the battle against . These advanced and sophisticated systems offer significant advantages, including enhanced drug protection, controlled release, and targeted delivery to specific tissues. Nanoparticles, in particular, show promise in combating infection through a variety of mechanisms, including direct drug delivery into the bacteria and the destruction of bacterial walls, as well as generation of free radicals. This review provides an overview of the current therapeutic landscape, including both existing and evolving treatment options. It delves into the transformative potential of novel drug delivery systems, including micro- and nanoparticles, to play a transformative role in the complex field of infection treatment. By examining the complex relationship between infection dynamics and cutting-edge delivery technologies, this review seeks to identify avenues for more effective and targeted interventions against this persistent threat. As our understanding of infection advances, new treatments and enhanced drug delivery methods offer the prospect of a more effective and personalized approach to combating this persistent health problem. This dynamic intersection of microbiology and nanotechnology exemplifies the relentless pursuit of innovative solutions to safeguard against the formidable challenges posed by . Ultimately, it offers hope for improved patient outcomes and a healthier population.
众所周知，感染是胃炎的主要病因。如果不加以治疗，这种感染发展成胃癌的可能性令人担忧。然而，抗生素耐药性的不断增加以及复杂的多药和高剂量治疗方案的必要性削弱了传统治疗的效果。此外，生物膜形成、外排泵和基因突变等因素的存在显著增加了治疗失败的风险。鉴于这些重大挑战，当代药物递送系统是对抗[此处原文缺失具体疾病名称]的重要辅助手段。这些先进而精密的系统具有显著优势，包括增强药物保护、控释以及靶向递送至特定组织。特别是纳米颗粒，通过多种机制在对抗[此处原文缺失具体疾病名称]感染方面显示出前景，包括将药物直接递送至细菌内、破坏细菌细胞壁以及产生自由基。本综述概述了当前的治疗格局，包括现有的和不断发展的治疗选择。它深入探讨了新型药物递送系统（包括微米和纳米颗粒）在复杂的[此处原文缺失具体疾病名称]感染治疗领域发挥变革性作用的潜力。通过研究感染动态与前沿递送技术之间的复杂关系，本综述旨在确定针对这一持续威胁的更有效和靶向干预途径。随着我们对[此处原文缺失具体疾病名称]感染的认识不断深入，新的治疗方法和改进的药物递送方法为对抗这一持续存在 的健康问题提供了更有效和个性化方法的前景。微生物学和纳米技术的这种动态交叉体现了对创新解决方案的不懈追求，以防范[此处原文缺失具体疾病名称]带来的巨大挑战。最终，它为改善患者预后和实现更健康的人群带来了希望。
